NRG4 and metabolic dysfunction-associated steatotic liver disease: They demonstrate that NRG4 derived from brown fat represses hepatic lipogenesis through the signaling of human epidermal growth factor receptor 3 (ErbB3, HER3) and ErbB4 (HER4), ultimately leading to the inhibition of nonalcoholic fatty liver disease (NAFLD) [105].